搜索结果: 1-5 共查到“临床医学其他学科 leukotriene”相关记录5条 . 查询时间(0.006 秒)
A Double-Blind Non-inferiority Clinical Study of Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, Compared with Pranlukast in Patients with Seasonal Allergic Rhinitis
comparative double blind study cysteinyl leukotriene receptor montelukast pranlukast seasonal allergic rhinitis
2010/11/17
Montelukast 5mg, 10mg once daily and the pranlukast 450mg/day showed significant improvements in the change from the baseline in the composite, daytime and nighttime nasal symptom scores, and the impr...
Therapeutic Effect of Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, on Japanese Patients with Seasonal Allergic Rhinitis
cysteinyl leukotriene receptor dose-response relationship montelukast rhinitis allergic seasonal
2010/11/17
Background: Secretion of nasal discharge was enhanced and airway-resistance in the nasal cavity was augmented, resulting in nasal congestion, when leukotrienes were administered to the nasal mucosa. T...
Clinical Evaluation of Leukotriene Receptor Antagonists in Preventing Common Cold-like Symptoms in Bronchial Asthma Patients
acute exacerbation asthma common cold-like symptoms ICS LTRAs
2010/11/18
Adult asthma patients undergoing treatment with LTRAs exhibit lower incidence rates of common cold-like symptoms than those not receiving LTRAs. LTRAs play an important role in reducing the incidence ...
Population-based open-label clinical effectiveness assessment of the cysteinyl leukotriene receptor antagonist pranlukast
asthma pranlukast questionnaire symptom treatment
2010/11/26
Although the efficacy of cysteinyl leukotriene receptor antagonists in asthma therapy has been established through controlled clinical trials, there are no data concerning the effectiveness of their u...
Effect of a leukotriene receptor antagonist on the prevention of recurrent asthma attacks after an emergency room visit
β2-adrenergic receptor agonist asthma exacerbation leukotriene receptor antagonist montelukast
2010/11/24
In the montelukast group, the need for a rescue β-adrenergic receptor agonist was significantly decreased; 54.5% of patients in the montelukast group required use of β-adrenergic receptor agonist comp...